David J. Safronetz - Infectious Diseases

Author Information

David J. Safronetz is a notable researcher affiliated with the Zoonotic Diseases and Special Pathogens division at the National Microbiology Laboratory, part of the Public Health Agency of Canada. He is also associated with the Department of Medical Microbiology at the University of Manitoba. His research focuses on infectious diseases, particularly zoonotic and viral pathogens, and he has significant experience in investigating emerging diseases and developing protective strategies against them.

Research Contributions

David J. Safronetz has made significant contributions to the field of infectious diseases, with a particular emphasis on viral pathogens such as Ebola, SARS-CoV-2, and Lassa virus. His work includes the study of persistent infections, vaccine development, and disease dynamics in animal models. Notable recent research includes the development of recombinant vaccines that protect against SARS-CoV-2 and studies on viral replication kinetics and host responses. His research also covers the development of synthetic vaccines and the use of novel antibody treatments to combat lethal viral infections.

Aliases

David J. Safronetz is also known by several variations of his name, including D Safronetz, D. Safronetz, David Safronetz, and Dave Safronetz.

Publication and Citation Metrics

Metric	Value
Citation Count	5400
H-index	44
Paper Count	176

Publications:

Persistent Ebola Virus Infection within the Male Reproductive Tract is Related to Both Viral Replication Kinetics and Host Response at the Blood-Testis Barrier

DOI: 10.2139/ssrn.4000892

Year: 2022

Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease

DOI: 10.1128/jvi.00389-22

Year: 2022

Hematology and Clinical Chemistry Reference Ranges for Laboratory-Bred Natal Multimammate Mice (Mastomys natalensis)

DOI: 10.3390/v13020187

Year: 2021

Exposure route, sex, and age influence disease outcome in a golden Syrian hamster model of SARS-CoV-2 infection

DOI: 10.1101/2021.06.12.448196

Year: 2021

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

DOI: 10.1371/journal.pcbi.1008535

Year: 2021

Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages

DOI: 10.1016/j.isci.2021.103328

Year: 2021

Polyclonal alpaca antibodies protect against hantavirus pulmonary syndrome in a lethal Syrian hamster model

DOI: 10.1038/s41598-021-96884-6

Year: 2021

Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease

DOI: 10.1101/2021.12.02.470987

Year: 2021

Hematologic and serum biochemistry reference intervals using defined ASCVP methodology for laboratory natal multimammate mice (Mastomys natalensis)

DOI: 10.1177/00236772211018587

Year: 2021

Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease

DOI: 10.1016/j.isci.2021.103219

Year: 2021

Why Do Pathogens Alter Glycolysis?

What are the Challenges in Controlling Anopheles Mosquitoes?

What are B Cells?

What is Inherited Immunity?

How Does PCR Work?

What Preventive Measures Can Be Taken?

How is Ebola Transmitted?

What are drug interactions?

How is Cervical Cancer Diagnosed?

What is the Global Impact of Measles?

Partnered Content Networks

Relevant Topics